Advances in small bowel neuroendocrine neoplasia

Michaela S. Banck, Andreas S Beutler

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: This review aims at summarizing progress in clinical trials and basic science redefining the diagnosis and treatment of well differentiated small intestine neuroendocrine tumors (SI-NET). RECENT FINDINGS: Two clinical trials demonstrated antitumor activity of the long-acting somatostatin analogues octreotide long-acting release and lanreotide for advanced SI-NET. The mammalian target of rapamycin (mTOR) inhibitor everolimus is another treatment option for patients with SI-NET, but awaits definitive proof of benefit in the ongoing RAD001 In Advanced Neuroendocrine Tumors study (RADIANT-4). Two whole exome/genome-sequencing studies reported in the past year provided the first genome-wide analysis of large sets of SI-NET at nucleotide resolution. Candidate therapeutically relevant alterations were found to affect SRC, SMAD genes, aurora kinase A, epidermal growth factor receptor, heat shock protein 90, and platelet-derived growth factor receptor as well as mutually exclusive amplification of RAC-alpha serine/threonine-protein kinase (AKT1) or AKT2 and other alterations of PI3K/Akt/mTOR signaling genes. The gene CDKN1B is inactivated by small insertions/deletions in 8% of patients with SI-NET suggesting cell cycle inhibitors as new candidate drugs for SI-NET. Circulating tumor cells and tumor-derived RNA in the blood are promising clinical tests for SI-NET. SUMMARY: Clinical and genomic research may merge in the near future to re-shape clinical trials and to define the 'personalized' treatment options for patients with SI-NET.

Original languageEnglish (US)
Pages (from-to)163-167
Number of pages5
JournalCurrent Opinion in Gastroenterology
Volume30
Issue number2
DOIs
StatePublished - Mar 2014

Fingerprint

Neuroendocrine Tumors
Small Intestine
Neoplasms
Clinical Trials
Sirolimus
Aurora Kinase A
Genome
Genes
Exome
Circulating Neoplastic Cells
HSP90 Heat-Shock Proteins
Platelet-Derived Growth Factor Receptors
Octreotide
Protein-Serine-Threonine Kinases
Somatostatin
Phosphatidylinositol 3-Kinases
Epidermal Growth Factor Receptor
Cell Cycle
Therapeutics
Nucleotides

Keywords

  • Genome sequencing
  • Small bowel carcinoid
  • Small intestine neuroendocrine tumor
  • Somatostatin analogue

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Advances in small bowel neuroendocrine neoplasia. / Banck, Michaela S.; Beutler, Andreas S.

In: Current Opinion in Gastroenterology, Vol. 30, No. 2, 03.2014, p. 163-167.

Research output: Contribution to journalArticle

@article{b6ebe83636ca4ad499b015d4d06d9956,
title = "Advances in small bowel neuroendocrine neoplasia",
abstract = "PURPOSE OF REVIEW: This review aims at summarizing progress in clinical trials and basic science redefining the diagnosis and treatment of well differentiated small intestine neuroendocrine tumors (SI-NET). RECENT FINDINGS: Two clinical trials demonstrated antitumor activity of the long-acting somatostatin analogues octreotide long-acting release and lanreotide for advanced SI-NET. The mammalian target of rapamycin (mTOR) inhibitor everolimus is another treatment option for patients with SI-NET, but awaits definitive proof of benefit in the ongoing RAD001 In Advanced Neuroendocrine Tumors study (RADIANT-4). Two whole exome/genome-sequencing studies reported in the past year provided the first genome-wide analysis of large sets of SI-NET at nucleotide resolution. Candidate therapeutically relevant alterations were found to affect SRC, SMAD genes, aurora kinase A, epidermal growth factor receptor, heat shock protein 90, and platelet-derived growth factor receptor as well as mutually exclusive amplification of RAC-alpha serine/threonine-protein kinase (AKT1) or AKT2 and other alterations of PI3K/Akt/mTOR signaling genes. The gene CDKN1B is inactivated by small insertions/deletions in 8{\%} of patients with SI-NET suggesting cell cycle inhibitors as new candidate drugs for SI-NET. Circulating tumor cells and tumor-derived RNA in the blood are promising clinical tests for SI-NET. SUMMARY: Clinical and genomic research may merge in the near future to re-shape clinical trials and to define the 'personalized' treatment options for patients with SI-NET.",
keywords = "Genome sequencing, Small bowel carcinoid, Small intestine neuroendocrine tumor, Somatostatin analogue",
author = "Banck, {Michaela S.} and Beutler, {Andreas S}",
year = "2014",
month = "3",
doi = "10.1097/MOG.0000000000000043",
language = "English (US)",
volume = "30",
pages = "163--167",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Advances in small bowel neuroendocrine neoplasia

AU - Banck, Michaela S.

AU - Beutler, Andreas S

PY - 2014/3

Y1 - 2014/3

N2 - PURPOSE OF REVIEW: This review aims at summarizing progress in clinical trials and basic science redefining the diagnosis and treatment of well differentiated small intestine neuroendocrine tumors (SI-NET). RECENT FINDINGS: Two clinical trials demonstrated antitumor activity of the long-acting somatostatin analogues octreotide long-acting release and lanreotide for advanced SI-NET. The mammalian target of rapamycin (mTOR) inhibitor everolimus is another treatment option for patients with SI-NET, but awaits definitive proof of benefit in the ongoing RAD001 In Advanced Neuroendocrine Tumors study (RADIANT-4). Two whole exome/genome-sequencing studies reported in the past year provided the first genome-wide analysis of large sets of SI-NET at nucleotide resolution. Candidate therapeutically relevant alterations were found to affect SRC, SMAD genes, aurora kinase A, epidermal growth factor receptor, heat shock protein 90, and platelet-derived growth factor receptor as well as mutually exclusive amplification of RAC-alpha serine/threonine-protein kinase (AKT1) or AKT2 and other alterations of PI3K/Akt/mTOR signaling genes. The gene CDKN1B is inactivated by small insertions/deletions in 8% of patients with SI-NET suggesting cell cycle inhibitors as new candidate drugs for SI-NET. Circulating tumor cells and tumor-derived RNA in the blood are promising clinical tests for SI-NET. SUMMARY: Clinical and genomic research may merge in the near future to re-shape clinical trials and to define the 'personalized' treatment options for patients with SI-NET.

AB - PURPOSE OF REVIEW: This review aims at summarizing progress in clinical trials and basic science redefining the diagnosis and treatment of well differentiated small intestine neuroendocrine tumors (SI-NET). RECENT FINDINGS: Two clinical trials demonstrated antitumor activity of the long-acting somatostatin analogues octreotide long-acting release and lanreotide for advanced SI-NET. The mammalian target of rapamycin (mTOR) inhibitor everolimus is another treatment option for patients with SI-NET, but awaits definitive proof of benefit in the ongoing RAD001 In Advanced Neuroendocrine Tumors study (RADIANT-4). Two whole exome/genome-sequencing studies reported in the past year provided the first genome-wide analysis of large sets of SI-NET at nucleotide resolution. Candidate therapeutically relevant alterations were found to affect SRC, SMAD genes, aurora kinase A, epidermal growth factor receptor, heat shock protein 90, and platelet-derived growth factor receptor as well as mutually exclusive amplification of RAC-alpha serine/threonine-protein kinase (AKT1) or AKT2 and other alterations of PI3K/Akt/mTOR signaling genes. The gene CDKN1B is inactivated by small insertions/deletions in 8% of patients with SI-NET suggesting cell cycle inhibitors as new candidate drugs for SI-NET. Circulating tumor cells and tumor-derived RNA in the blood are promising clinical tests for SI-NET. SUMMARY: Clinical and genomic research may merge in the near future to re-shape clinical trials and to define the 'personalized' treatment options for patients with SI-NET.

KW - Genome sequencing

KW - Small bowel carcinoid

KW - Small intestine neuroendocrine tumor

KW - Somatostatin analogue

UR - http://www.scopus.com/inward/record.url?scp=84894041624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894041624&partnerID=8YFLogxK

U2 - 10.1097/MOG.0000000000000043

DO - 10.1097/MOG.0000000000000043

M3 - Article

C2 - 24441281

AN - SCOPUS:84894041624

VL - 30

SP - 163

EP - 167

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 2

ER -